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patients decreased continuously for two years after the end of
treatment [9]. Therefore, an additional effect of TVR may be that
it leads to lower risk of the development of HCC.
In summary, our study conﬁrmed a lower incidence of HCC in
patients with TVR compared to those with NVR, probably because
TVR was associated with benign clinical outcomes.
We thank the Journal of Hepatology for providing the opportu-
nity for us to engage in this interesting discussion.
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Understanding triphasic HCV decline during treatment in the era
of IL28B polymorphisms and direct acting antiviral agents
via mathematical modeling
To the Editor:
Howell and colleagues [1] have recently provided important
insights into the relationship among viral kinetic patterns,
including the triphasic pattern (Fig. 1 in [1]), ethnicity (African
Americans, AA, and Caucasian Americans, CA) and IL28B geno-
types (rs12979860; CC, TC and TT genotypes) during pegylated
interferon-alpha-2a (PegIFNa-2a) + ribavirin (RBV) treatment.
Their study strongly suggested differences in viral kinetic pat-
terns under PegIFNa-2a ± RBV between AA and CA are associated
with IL28B genotypes and elegantly showed that the difference
disappears in AA or CA subjects with the same favorable allele
(CC). Interestingly, Howell et al. described subjects in whom a
static or increasing viral phase (termed here a shoulder) was
observed during days 2–7 after treatment initiation (Fig. 1 in
[1]). While the nature of the shoulder phase is still not known,
Howell et al. [1] related this phase to ‘‘a delay in the pharmaco-
logic activity of ribavirin’’ or ‘‘lower PegIFNa-2a effectiveness’’.
We sought here to clarify the current theory behind the nature
of the shoulder phase and provide further insights into the
subject.
A transient viral decline was observed in some HCV-monoin-
fected subjects during the ﬁrst week of RBV monotherapy [2]. In a
recent study, in which subjects were treated with RBV alone for
4 weeks, there was no association between HCV RNA kinetics
measured weekly and IL28B genotypes (submitted). In HIV/HCV
co-infected subjects treated with PegIFNa-2b and RBV, median
RBV area under the curve levels were lower in sustained viral
responders (SVRs) compared with non-SVRs at days 3 and 7
and were associated with a continued viral decline during days
3–7 (in SVRs) compared to a shoulder in non-SVRs (Fig. 2C in
[3]). Unfortunately, data on IL28B genotypes is not yet available
to be linked to our previous studies [2,3], but if indeed subjects
with IL28B CC genotypes in Howell et al. are associated with early
lower RBV levels and/or transient viral decline during the ﬁrst
week, then it could, partly, explain their ﬁndings.
A more evident cause of the viral shoulder phase is the known
pharmacokinetics of PegIFNawhich peaks and then declines dur-
ing the ﬁrst week of treatment [4,5]. To explain the shoulder
phase with the standard model [6], the PegIFNa concentration
in serum, C(t), was coupled with its effectiveness, e(t), in blocking
viral production/release [4,5] (see Fig. 1 for equations and param-
eters deﬁnition). Using this theory, the observed viral kinetic pat-
terns from Howell et al. can be predicted (Fig. 1). Interestingly, we
recently showed, in HIV/HCV (genotype 1/3) co-infected subjects
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treated with PegIFNa-2a + RBV, that the signiﬁcantly higher
effectiveness in subjects with CC genotype was associated with
signiﬁcantly lower EC50 (median 1.3) compared to TC/TT subjects
(median 3.3) [7]. In addition, the second phase of viral decline
was faster and the infected cell loss rate, d, was larger in CC than
in TC/CC subjects (d = 0.25 vs. 0.13 d1) [7]. Accordingly, the
higher PegIFNa-2a effectiveness and the continued viral decline
between days 2 and 7 in subjects with a CC genotype from
Howell et al. may be partly related to lower EC50 and higher d,
compared to TC/TT patients (Fig. 1; black vs. grey/blue lines).
Model simulations suggest that the shoulder phase in CT/TT
genotype patients is not necessarily due to low PegIFNa-2a effec-
tiveness, but may also be due to lower d. Clearly, further studies
that combine PegIFNa-2a and RBV pharmacokinetics/pharmaco-
dynamics with frequent viral kinetics during the ﬁrst week of
treatment are necessary to pinpoint the causes of the shoulder
phase observed in TC/TT subjects.
While individual viral kinetics were not shown by Howell
et al., it might be true that some patients experienced a longer
(up to day 28) shoulder phase as previously documented [4,8],
and with a higher proportion in subjects with TT/TC genotypes
compared to CC, as recently observed by de Araujo et al. in
HIV/HCV co-infected subjects [7]. This longer shoulder phase
is explained by other mechanisms that are not related to
PegIFNa-2a pharmacokinetics/pharmacodynamics as described
in [4,8,9].
In the era of direct-acting antiviral agents (DAAs) against HCV,
it is important to note that the aforementioned shoulder phase is
not commonly seen (e.g., one case in supplementary material of
[10]). This may be attributed to the ability of DAAs not only to
reduce the synthesis of new intracellular HCV RNA, vRNA, but
also to enhance the degradation of vRNA. Based on this theory,
the shoulder phase is not observed as intracellular vRNA contin-
uously declines and thus, the overall production of virions
declines as well, even if the DAA is combined with PegIFNa-2a
and its effectiveness declines during the ﬁrst week of treatment.
However, PegIFNa + RBV is still the backbone of the current
standard of care and is also used as a lead-in in some protocols,
the existence of the shoulder phase is still relevant and should
be further explored in order to better optimize the standard
of care.
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Fig. 1. Predicting the viral kinetic patterns observed in Howell et al. during the
ﬁrst week of PegIFNa-2a + RBV treatment using the standard model of HCV
infection [6] but allowing the drug effectiveness, (eðtÞ ¼ CðtÞn=ðECn50 þ CðtÞnÞ
dashed lines), to vary with PegIFNa-2a concentration, (CðtÞ ¼ FD=V dkaðke  kaÞ
ðeka t  eka tÞ), where the PegIFNa-2a dose, D, is assumed to reach the injection
site immediately, is absorbed into the blood with rate constant ka, is
eliminated from the blood with rate constant ke, and is distributed through
a volume Vd where only a fraction, F, of the drug is bioavailable. The constant
EC50 is the PegIFNa-2a concentration at which drug’s effectiveness in blocking
viral production is half its maximum and n is a parameter called the Hill
coefﬁcient, which determines how steeply the effectiveness rises with increasing
drug concentration [4]. Predicted HCV RNA kinetics (solid lines) and its related
PegIFNa-2a effectiveness (dashed lines) are represented with the same color. Here
we show that this model can generate a shoulder (grey line). Further, while EC50
affects PegIFNa-2a effectiveness, the loss rate of infected cells, d, of the standard
model [6] dictates if viral load will increase, plateau or decrease until day 7. Since
only EC50 and d (values shown in Fig. 1) were found signiﬁcantly different between
subjects with CC and TC/TT genotypes [7], other model parameters were ﬁxed to
the median values found in [4] as follows: FD/Vd = 15 ng/ml; ka = 1 d1; ke = 0.1 -
d1; n = 2. The other parameter of the standard model [6], i.e., the viral clearance
rate, c, was ﬁxed to 6 d1.
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Reply to: ‘‘Understanding triphasic HCV decline during treatment
in the era of IL28B polymorphisms and direct acting antiviral
agents via mathematical modeling’’
Triphasic decline in HCV RNA during peginterferon and
ribavirin therapy for HCV genotype 1
To the Editor:
We thank Dahari et al. for their comments on our recent
manuscript investigating the relationship between IL28B SNP
12979860 and early HCV RNA kinetics in 173 African American
(AA) and 188 Caucasian American (CA) patients infected with
chronic HCV genotype 1, during peginterferon alfa-2a and ribavi-
rin (PegIFN-a-2a/RBV) therapy in the VIRAHEP-C study [1]. Com-
pared to SNP C/T and T/T genotypes, the C/C genotype was
associated with greater phase 1 and faster phase 2 declines in
HCV RNA in both AA and CA patients. Thus, we concluded that
this SNP predicts both interferon (IFN) effectiveness at blocking
HCV production (i.e., phase 1) and clearance of infected hepato-
cytes (i.e., phase 2), and that this could explain how the IL28B
SNP 12979860 C/C genotype increases the probability of SVR
(compared to non-C/C genotypes) following PegIFN-a-2a/RBV
treatment for HCV genotype 1. Differences in early viral kinetics
between AA and CA could be largely explained by racial differ-
ences in the frequency of the IL28B SNP C allele.
Patients with IL28B SNP non-C/C genotypes were more likely
to have either a static phase or an increase in serum HCV RNA
(i.e., shoulder) from day 2–7. We hypothesized that the IL28B
SNP-related variability in the shoulder phase was due primarily
to differences in IFN effectiveness (SNP C/C > C/T and T/T), as
the decline in HCV RNA from day 2–7 was more strongly corre-
lated with the magnitude of phase 1 than the phase 2 slope. In
addition, we noted that the rebound in HCV RNA was temporally
related to the decline in serum peginterferon from day 2/3 to 7
between the ﬁrst and second injection [2]. Furthermore, we cited
evidence that ribavirin also plays a signiﬁcant role in regulating
viral kinetics between day 2–7 [3]. It is known that ribavirin
has no effect on phase 1, either when administered alone or
when combined with peginterferon alfa; when combined with
peginterferon, it prevents an increase (rebound) in HCV RNA
from day 2–7 and accelerates the fall in HCV RNA from day
7–28 (phase 2), in patients with an adequate ﬁrst phase response
[3]. With regard to ribavirin, viral kinetics models that include
ribavirin and IFN effectiveness are better able to explain
early HCV RNA kinetics than models with IFN effectiveness
alone [4]. According to this model, the requirement for ribavirin
during phase 2 is inversely related to IFN effectiveness. Thus,
phase 2 and SVR in patients with IL28B SNP C/C are expected to
be less dependent on ribavirin than in patients with non-C/C
genotypes.
In their letter, Dahari et al. reviewed the prevailing concepts
of the shoulder phase from day 2–7 incorporating observations
from 2 studies of US and Brazilian patients who were co-infected
with HCV and HIV [5,6]. These studies are limited by small sam-
ple sizes and inclusion of patients with HCV genotypes 2 and 3.
Analogous to our study, patients in one study were stratiﬁed by
IL28B SNP genotype [6]. In keeping with our results, HCV geno-
type 1, co-infected patients with SNP C/C genotypes had signiﬁ-
cantly higher ﬁrst (day 0–2) and second (day 2–29) phase
declines in serum HCV RNA [6]. In addition, the peginterferon alfa
serum concentration associated with half maximum IFN effec-
tiveness (EC50) was lower in patients with IL28B SNP C/C geno-
types compared to non-C/C genotypes (p = 0.02), suggesting
that patients with C/C genotype were more sensitive to peginter-
feron. Dahari et al. suggested that the faster declines in serum
HCV RNA from day 2–7 in patients with IL28B SNP C/C in our
study may be partly related to greater IFN sensitivity (peginter-
feron EC50) and a higher infected cell loss rate. Our results are
consistent with the concept that the shoulder phase reﬂects both
IFN effectiveness and the infected cell loss rate. The peginterferon
EC50 (IFN sensitivity) hypothesis is intriguing. However, the dif-
ference in peginterferon EC50 between C/C and non-C/C geno-
types was not signiﬁcant in HIV-co-infected patients with HCV
genotype 1 (p = 0.6), possibly due to inadequate statistical power.
Studies with larger numbers of patients infected with HCV geno-
type 1 alone are needed to address this question and to deter-
mine if peginterferon EC50 is an independent predictor of the
shoulder and second phase responses.
In another study, Dahari et al. observed signiﬁcantly lower
ribavirin plasma concentrations during the ﬁrst 2 weeks and
lower ribavirin exposure or area under the concentration–time
curve (AUC) levels at days 3, 7, 14, and 28 of peginterferon alfa
combination treatment in HCV-HIV co-infected patients who
achieved an SVR relative to those without an SVR [5]. They raised
the possibility that lower early ribavirin levels in patients with
IL28B CC genotypes might explain the transient viral declines
and shoulder phase during the ﬁrst week in our report. In more
recent studies, we have investigated the importance of ribavirin
pharmacokinetics to the lower efﬁcacy of peginterferon and riba-
virin therapy in AA compared to CA with HCV genotype 1 [7,8].
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